Latest Regulatory Development News

Aussie Broadband has agreed to acquire AGL Telco’s telecommunications assets, adding 350,000 broadband and mobile connections and forming a long-term exclusive partnership with AGL. This deal positions Aussie Broadband as Australia’s third largest NBN provider.

Commonwealth Bank of Australia’s latest Basel III Pillar 3 disclosures reveal steady capital adequacy ratios and proactive adaptation to evolving regulatory standards as of December 2025.

Fortuna Metals has reported significant high-grade rutile mineralisation at its Mkanda project in Malawi, with assays from 96 drill holes revealing a mineralised footprint extending over 25km. The Malawi government has confirmed the company’s exemption from raw mineral export restrictions, supporting its in-country beneficiation plans.

News Corporation reported a 4% revenue increase to US$4.506 billion for the half-year ended December 2025, while net income declined 9% to US$305 million. The company declared an interim dividend and continued its stock repurchase program amid mixed segment performances and ongoing legal challenges.

Manuka Resources’ subsidiary Trans-Tasman Resources has received a draft decision proposing to decline consent for its Taranaki VTM iron sands project, challenging the company’s plans to develop a critical minerals supply in New Zealand.

The US Congress has reauthorized the Rare Pediatric Disease Priority Review Voucher program through September 2029, a move that could significantly benefit Neuren Pharmaceuticals as it advances its rare disease drug candidates.

OncoSil Medical Limited has announced a fully underwritten $2 million entitlement offer alongside a $6 million placement to fund its clinical and commercial growth initiatives. The capital raising includes new shares and options, with shareholder approvals pending for certain components.

Small caps did the heavy lifting this week, led by two big discovery stories in resources. Funding raises and takeover moves kept attention on who can pay for the next step, not just promise it.

A handful of healthcare names did the heavy lifting this week, driven by FDA wins, guideline upgrades, and big shifts in sales and cashflow. The flip side: several clinical-stage stocks fell hard as investors stayed picky about near-term proof and funding.

PT ANTAM Tbk reported record production and sales volumes for nickel ore, bauxite, and alumina in FY25, driven by strong domestic demand and operational efficiencies. The company also progressed key downstream projects and strengthened its ESG leadership with multiple awards.

Golden Cross Resources reported a quiet December quarter with ongoing preparatory work at its flagship Copper Hill copper-gold project, while its ASX securities remain suspended pending operational compliance.

Northern Minerals has made significant strides in developing its Browns Range Heavy Rare Earths Project, securing substantial funding support from US and Australian agencies alongside a $60.5 million capital raise. Exploration success and engineering progress position the company for a Final Investment Decision by late 2026.